NCT03231683View on ClinicalTrials.gov

Use of S+Ketamine During Target-Controlled Intravenous Anaesthesia After Abdominal Hysterectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
KetamineAnesthesiaMorphineHysterectomy
Interventions
DRUG

Esketamine

intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model

DRUG

Saline

intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model

DRUG

Remifentanil

Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model

DRUG

Propofol

Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model

Trial Locations (1)

229899

Kk Women'S and Children'S Hospital, Singapore

All Listed Sponsors
lead

KK Women's and Children's Hospital

OTHER_GOV

NCT03231683 - Use of S+Ketamine During Target-Controlled Intravenous Anaesthesia After Abdominal Hysterectomy | Biotech Hunter | Biotech Hunter